Jubilant Pharmova Limited (JUBLPHARMA.NS)

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of pulmonary embolism, cancer, coronary artery disease, and other diseases. Its Allergy Immunotherapy segment provides specialized diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacture, distribution, sale, and marketing of generic formulations for therapeutic areas, such as cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment provides drug discovery services and active pharmaceutical ingredients. Its Proprietary Novel Drugs segment offers patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organizations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.